Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

Original reporting
Published Nov 4, 2026, 3:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ardelyx (ARDX) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ARDXBullishMed
01

Why it matters

The earnings data offers fresh insight into Ardelyx's financial health and may prompt short‑term trading adjustments.

02

Market read

First‑time earnings disclosure for Q3 2026, material for traders tracking biotech earnings.

03

What to watch

Potential upcoming regulatory decisions on IBSRELA could outweigh the earnings impact.

Relevance 7/10Novelty 8/10Timing: post‑earnings today

Background

Ardelyx provided its Q3 2026 earnings call, highlighting revenue growth, loss narrowing, and cash balance.

Company-level read

Ticker impact

$ARDXBullishHigh confidence
Context

Q3 2026 earnings call disclosed total product revenue $125.5M, net loss $0.7M, cash $285.3M and reaffirmed full-year guidance.

Expected impact

likely modest upside as the market prices in the narrowed loss and reaffirmed guidance

Evidence & confidence

The company reported better-than-expected loss reduction and solid cash, which typically supports a short-term price lift.

Market effects

Biotech earnings season may influence peer valuations, especially other gut‑microbiome players.

U.S. biotech sector sees slight positive pressure.

Limited to investors tracking U.S. biotech earnings.

Counterpoint

If the market had already priced in the guidance reaffirmation, the earnings may not move the stock significantly.

Key entities

  • Ardelyx

    U.S. biotech firm focused on kidney disease therapies.

Related articles

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.

$ARDXMed

Ardelyx completes enrollment in constipation drug trial

Ardelyx Inc. (ARDX) completed enrollment in its Phase 3 ACCEL trial for IBSRELA (tenapanor) in treating chronic idiopathic constipation, ahead of schedule. Topline data is expected in the second half of 2027. IBSRELA is currently approved for irritable bowel syndrome with constipation in adults. The trial's primary endpoint is assessing the drug's durable efficacy in relieving constipation.